The Europe Opioid Use Disorder (OUD) Market would witness market growth of 9.4% CAGR during the forecast period (2023-2030).
Medication-Assisted Treatment (MAT) utilizing an opioid agonist or opioid antagonist is the foundation for present therapies. MAT incorporates drugs that lessen cravings and withdrawal symptoms without causing the exhilaration that the original drug provided. MAT, which is beneficial in treating OUD and can assist some people in maintaining recovery, involves using medications in conjunction with counseling, and behavioral therapy.
The medications are generally accessible and have been made generic in many areas. However, many of these medications have recently undergone reformulations and been introduced. Reformulations and a cutting-edge mode of action are the primary concerns of pipeline medicines for treating opioid addiction. Over the forecast period, one of the main drivers of the market for opioid use disorders is anticipated to be the commercialization of these agents.
Russia has a high prevalence of drug use and has had a broad outbreak of injectable drug use for some time. With an estimated 2% of the population using drugs through a vein, a total of 18,013 persons overdosed on illegal drugs in 2020, and 7,366 died as a consequence. This represents an increase of 16% from 2019. The establishment of treatment and preventative clinics could help reduce the issue. By striking the right balance between prevention, treatment, and later social rehabilitation, these facilities want to develop an efficient treatment model that will help the market thrive.
The Germany market dominated the Europe Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $371.4 million by 2030. The UK market is exhibiting a CAGR of 8.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 10.2% during (2023 - 2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Opioid Use Disorder (OUD) Market is Projected to reach USD 6.4 Billion by 2030, at a CAGR of 9.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 Europe Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 Europe Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 Europe Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. Europe Opioid Use Disorder (OUD) Market by Drug Class
4.1 Europe Buprenorphine Market by Country
4.2 Europe Methadone Market by Country
4.3 Europe Naltrexone Market by Country
Chapter 5. Europe Opioid Use Disorder (OUD) Market by Route of Administration
5.1 Europe Parenteral Market by Country
5.2 Europe Oral Market by Country
Chapter 6. Europe Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 Europe Hospital Pharmacies Market by Country
6.2 Europe Retail Pharmacies & Stores Market by Country
6.3 Europe Online Pharmacies Market by Country
Chapter 7. Europe Opioid Use Disorder (OUD) Market by Country
7.1 Germany Opioid Use Disorder (OUD) Market
7.1.1 Germany Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 Germany Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 Germany Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 UK Opioid Use Disorder (OUD) Market
7.2.1 UK Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 UK Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 UK Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 France Opioid Use Disorder (OUD) Market
7.3.1 France Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 France Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 France Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 Russia Opioid Use Disorder (OUD) Market
7.4.1 Russia Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 Russia Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 Russia Opioid Use Disorder (OUD) Market by Distribution Channel
7.5 Spain Opioid Use Disorder (OUD) Market
7.5.1 Spain Opioid Use Disorder (OUD) Market by Drug Class
7.5.2 Spain Opioid Use Disorder (OUD) Market by Route of Administration
7.5.3 Spain Opioid Use Disorder (OUD) Market by Distribution Channel
7.6 Italy Opioid Use Disorder (OUD) Market
7.6.1 Italy Opioid Use Disorder (OUD) Market by Drug Class
7.6.2 Italy Opioid Use Disorder (OUD) Market by Route of Administration
7.6.3 Italy Opioid Use Disorder (OUD) Market by Distribution Channel
7.7 Rest of Europe Opioid Use Disorder (OUD) Market
7.7.1 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class
7.7.2 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration
7.7.3 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
TABLE 1 Europe Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 2 Europe Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 3 Europe Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 4 Europe Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 5 Europe Buprenorphine Market by Country, 2019 - 2022, USD Million
TABLE 6 Europe Buprenorphine Market by Country, 2023 - 2030, USD Million
TABLE 7 Europe Methadone Market by Country, 2019 - 2022, USD Million
TABLE 8 Europe Methadone Market by Country, 2023 - 2030, USD Million
TABLE 9 Europe Naltrexone Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Naltrexone Market by Country, 2023 - 2030, USD Million
TABLE 11 Europe Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 12 Europe Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 13 Europe Parenteral Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe Parenteral Market by Country, 2023 - 2030, USD Million
TABLE 15 Europe Oral Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Oral Market by Country, 2023 - 2030, USD Million
TABLE 17 Europe Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 Europe Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 21 Europe Retail Pharmacies & Stores Market by Country, 2019 - 2022, USD Million
TABLE 22 Europe Retail Pharmacies & Stores Market by Country, 2023 - 2030, USD Million
TABLE 23 Europe Online Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Online Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 25 Europe Opioid Use Disorder (OUD) Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe Opioid Use Disorder (OUD) Market by Country, 2023 - 2030, USD Million
TABLE 27 Germany Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 28 Germany Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 29 Germany Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 30 Germany Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 31 Germany Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 32 Germany Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 33 Germany Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 Germany Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 UK Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 36 UK Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 37 UK Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 UK Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 39 UK Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 40 UK Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 41 UK Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 UK Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 France Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 44 France Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 45 France Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 France Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 47 France Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 48 France Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 49 France Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 France Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Russia Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 52 Russia Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 53 Russia Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 Russia Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 55 Russia Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 56 Russia Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 57 Russia Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Russia Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Spain Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 60 Spain Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 61 Spain Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 Spain Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 63 Spain Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 64 Spain Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 65 Spain Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Spain Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Italy Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 68 Italy Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 69 Italy Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 70 Italy Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 71 Italy Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 72 Italy Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 73 Italy Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Italy Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of Europe Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
TABLE 76 Rest of Europe Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
TABLE 77 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
TABLE 78 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
TABLE 79 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
TABLE 80 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
TABLE 81 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information – Indivior PLC (Reckitt Benckiser Group plc)
TABLE 84 Key Information – collegium pharmaceutical
TABLE 85 Key Information – Orexo AB
TABLE 86 Key Information – Alkermes PLC
TABLE 87 Key Information – Titan Pharmaceuticals, Inc.
TABLE 88 Key Information – Camurus AB
TABLE 89 KEY INFORMATION – AstraZeneca PLC
TABLE 90 Key Information – Hikma Pharmaceuticals PLC
TABLE 91 Key information – Mallinckrodt PLC
TABLE 92 key information – Viatris, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Opioid Use Disorder (OUD) Market share by Drug Class, 2022
FIG 3 Europe Opioid Use Disorder (OUD) Market share by Drug Class, 2030
FIG 4 Europe Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2030, USD Million
FIG 5 Europe Opioid Use Disorder (OUD) Market share by Route of Administration, 2022
FIG 6 Europe Opioid Use Disorder (OUD) Market share by Route of Administration, 2030
FIG 7 Europe Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2030, USD Million
FIG 8 Europe Opioid Use Disorder (OUD) Market share by Distribution Channel, 2022
FIG 9 Europe Opioid Use Disorder (OUD) Market share by Distribution Channel, 2030
FIG 10 Europe Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 Europe Opioid Use Disorder (OUD) Market share by Country, 2022
FIG 12 Europe Opioid Use Disorder (OUD) Market share by Country, 2030
FIG 13 Europe Opioid Use Disorder (OUD) Market by Country, 2019 - 2030, USD Million